Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Biosciences Licenses Hybridization Technology from Applied Biosystems

NEW YORK, June 25 – Epoch Biosciences has licensed technology from Applied Biosystems for SNP detection and gene expression assays, the company said Monday. 

The technology, for using non-cleavable fluorescent self-quenching probes in hybridization assays, will be incorporated into the company’s assays for measuring gene expression and detecting SNPs. The company plans to release the first version of the assays this summer, in the launch of Epoch’s first product for the commercial market.

Epoch, based in Bothell, Wash., currently licenses its genetic analysis technology to Applied Biosystems and Third Wave Technologies, who use the technology for their commercial SNP detection and gene expression products.

Last year the company acquired Synthetic Genetics, a San Diego-based manufacturer of modified oligonucleotides, for $3.1 milion in cash.

"We are pleased to provide our probe technology to Epoch Biosciences as they near the release of their Eclipse probe line," Michael Lucero, vice president of applications marketing and R&D at Applied Biosystems, said in a statement.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.